New drug GVV858 shows promise in early trial for Hard-to-Treat breast cancer

NCT ID NCT07288359

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 14 times

Summary

This study tests a new drug, GVV858, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it works better when given alone or with hormone therapy. About 205 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Novartis Investigative Site
RECRUITING

Kyoto, 6068507, Japan
Novartis Investigative Site
RECRUITING

Singapore, 168583, Singapore
Novartis Investigative Site
RECRUITING

Taipei, 10002, Taiwan
Tennessee Oncology PLLC
RECRUITING

Nashville, Tennessee, 37203, United States

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED CCNE1-AMPLIFIED SOLID TUMORS ADVANCED HR+/HER2- BREAST CANCER METASTATIC CASTRATION-RESISTANT PROSTATE CANCER